



## Clinical trial results:

### A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis Summary

EudraCT number	2013-004533-32
Trial protocol	CZ PL
Global end of trial date	04 September 2018

#### Results information

Result version number	v2 (current)
This version publication date	21 September 2019
First version publication date	19 June 2016
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	109MS305
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01838668
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	225 Binney Street, Cambridge, Massachusetts, United States, 02142
Public contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com
Scientific contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	04 September 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 June 2015
Global end of trial reached?	Yes
Global end of trial date	04 September 2018
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The primary objective of Part I of the study is to determine the efficacy of BG00012 on inflammatory brain magnetic resonance imaging (MRI) lesion activity (gadolinium [Gd]-enhancing lesions) when compared with placebo from 4 scans performed at Weeks 12, 16, 20, and 24 in subjects with relapsing-remitting multiple sclerosis (RRMS) including subjects from the Asia-Pacific region. The primary objective of Part II of this study is to evaluate the long-term safety profile of BG00012 in eligible subjects from Part I.

Protection of trial subjects:

Written informed consent was obtained from each subject prior to evaluations being performed for eligibility. Subjects were given adequate time to review the information in the informed consent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study. Through the informed consent process each subject was made aware of the purpose of the study, the procedures, the benefits and risks of the study, the discomforts and the precautions taken. Any side effects or other health issues occurring during the study were followed up by the study doctor. Subjects were able to stop taking part in the study at any time without giving any reason.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 March 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	54 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Poland: 40
Country: Number of subjects enrolled	Czech Republic: 42
Country: Number of subjects enrolled	Japan: 115
Country: Number of subjects enrolled	Korea, Republic of: 20
Country: Number of subjects enrolled	Taiwan: 8
Worldwide total number of subjects	225
EEA total number of subjects	82

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	225
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study included a Screening Period (maximum of 28 days). A total of 225 subjects were randomized; however, 1 subject in the BG00012 240 mg twice a day (BID) arm was not dosed.

### Pre-assignment period milestones

Number of subjects started	225
Number of subjects completed	224

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Randomized but not dosed: 1
----------------------------	-----------------------------

### Period 1

Period 1 title	Part I (Double-blind Treatment Period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

BG00012 and placebo administration was double-blind. Placebo capsules matched BG00012 capsules in size, shape, color, and taste. Additionally, all subjects (including those receiving placebo) were dosed with the same number of capsules BID.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part I Placebo

Arm description:

Subjects randomized to placebo BID began dosing at 1 placebo capsule orally BID for the first 7 days and escalated to 2 placebo capsules orally BID from Day 8 through Week 24 (end of Part I).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

The pharmacist or designee dispensed at least a 4-week supply of study treatment to subjects at Baseline (Day 1/Enrollment Visit) and at each subsequent study visit through Week 24. Study treatment was not to be dispensed at Week 24 (except in the case of subjects continuing to Part II Extension Period) or at any Unscheduled Relapse Assessment Visit.

<b>Arm title</b>	Part I BG00012 240 mg BID
------------------	---------------------------

Arm description:

Subjects randomized to BG00012 began dosing at 120 mg BG00012 (1 capsule orally BID) for the first 7 days and escalated to 240 mg BG00012 (2 capsules orally BID) from Day 8 through Week 24 (end of Part I).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	BG00012
Investigational medicinal product code	BG00012
Other name	dimethyl fumarate, DMF, Tecfidera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

The pharmacist or designee dispensed at least a 4-week supply of study treatment to subjects at Baseline (Day 1/Enrollment Visit) and at each subsequent study visit through Week 24. Study treatment was not to be dispensed at Week 24 (except in the case of subjects continuing to Part II Extension Period) or at any Unscheduled Relapse Assessment Visit.

<b>Number of subjects in period 1<sup>[1]</sup></b>	<b>Part I Placebo</b>	<b>Part I BG00012 240 mg BID</b>
Started	113	111
Subjects dosed in Part I	113	111
Completed study drug in Part I	107 <sup>[2]</sup>	105
Completed study in Part I	108	105
Completed	108	105
Not completed	5	6
Consent withdrawn by subject	3	1
Adverse event, non-fatal	2	1
Not specified	-	4

**Notes:**

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 1 subject in the BG00012 240 mg BID arm was not dosed and is not included.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The number of subjects who completed study drug is included for reference. 1 subject did not complete study drug but did complete the study.

**Period 2**

Period 2 title	Part II (Open-label Treatment Period)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part II: Placebo/BG00012 240 mg BID (Switchers):

**Arm description:**

"PBO/BG12" – Subjects who received placebo in Part I before receiving BG00012 240 milligram (mg) BID in Part II for up to 4.5 years.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	BG00012
Investigational medicinal product code	BG00012
Other name	dimethyl fumarate, DMF, Tecfidera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

The pharmacist or designee dispensed at least a 4-week supply of study treatment to subjects at Baseline (Day 1/Enrollment Visit) and at each subsequent study visit through Week 24. Study treatment was not to be dispensed at Week 24 (except in the case of subjects continuing to Part II Extension Period) or at any Unscheduled Relapse Assessment Visit.

<b>Arm title</b>	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)
------------------	---

**Arm description:**

"BG12/BG12" - Subjects who received BG00012 240 mg BID in Part I, continued receiving BG00012 in Part II for up to 4.5 years.

Arm type	Experimental
Investigational medicinal product name	BG00012
Investigational medicinal product code	BG00012
Other name	dimethyl fumarate, DMF, Tecfidera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

The pharmacist or designee dispensed at least a 4-week supply of study treatment to subjects at Baseline (Day 1/Enrollment Visit) and at each subsequent study visit through Week 24. Study treatment was not to be dispensed at Week 24 (except in the case of subjects continuing to Part II Extension Period) or at any Unscheduled Relapse Assessment Visit.

<b>Number of subjects in period 2</b>	Part II: Placebo/BG00012 240 mg BID (Switchers):	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)
Started	108	105
Completed	0	2
Not completed	108	103
Adverse event, non-fatal	9	4
Investigator decision	2	3
Lost to follow-up	1	-
Reason not specified	83	82
Consent withdrawn	13	14

## Baseline characteristics

### Reporting groups

Reporting group title	Part I Placebo
-----------------------	----------------

Reporting group description:

Subjects randomized to placebo BID began dosing at 1 placebo capsule orally BID for the first 7 days and escalated to 2 placebo capsules orally BID from Day 8 through Week 24 (end of Part I).

Reporting group title	Part I BG00012 240 mg BID
-----------------------	---------------------------

Reporting group description:

Subjects randomized to BG00012 began dosing at 120 mg BG00012 (1 capsule orally BID) for the first 7 days and escalated to 240 mg BG00012 (2 capsules orally BID) from Day 8 through Week 24 (end of Part I).

Reporting group values	Part I Placebo	Part I BG00012 240 mg BID	Total
Number of subjects	113	111	224
Age categorical			
Units: Subjects			
18 to 19 years	0	0	0
20 to 29 years	23	20	43
30 to 39 years	57	45	102
40 to 49 years	29	37	66
50 to 55 years	3	9	12
> 55 years	1	0	1
Age continuous			
Units: years			
arithmetic mean	36	37.3	
standard deviation	± 7.46	± 8.27	-
Gender categorical			
Units: Subjects			
Female	84	78	162
Male	29	33	62

## End points

### End points reporting groups

Reporting group title	Part I Placebo
Reporting group description: Subjects randomized to placebo BID began dosing at 1 placebo capsule orally BID for the first 7 days and escalated to 2 placebo capsules orally BID from Day 8 through Week 24 (end of Part I).	
Reporting group title	Part I BG00012 240 mg BID
Reporting group description: Subjects randomized to BG00012 began dosing at 120 mg BG00012 (1 capsule orally BID) for the first 7 days and escalated to 240 mg BG00012 (2 capsules orally BID) from Day 8 through Week 24 (end of Part I).	
Reporting group title	Part II: Placebo/BG00012 240 mg BID (Switchers):
Reporting group description: "PBO/BG12" – Subjects who received placebo in Part I before receiving BG00012 240 milligram (mg) BID in Part II for up to 4.5 years.	
Reporting group title	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)
Reporting group description: "BG12/BG12" - Subjects who received BG00012 240 mg BID in Part I, continued receiving BG00012 in Part II for up to 4.5 years.	
Subject analysis set title	ITT Population: Placebo
Subject analysis set type	Intention-to-treat
Subject analysis set description: ITT Population: subjects who were randomized to placebo and received at least 1 dose of study treatment.	
Subject analysis set title	ITT Population: BG00012 240 mg BID
Subject analysis set type	Intention-to-treat
Subject analysis set description: ITT Population: subjects who were randomized to BG00012 and received at least 1 dose of study treatment.	

### Primary: MRI: Total Number of New Gd-Enhancing Lesions From Scans at Week 12 to 24: Part I

End point title	MRI: Total Number of New Gd-Enhancing Lesions From Scans at Week 12 to 24: Part I
End point description: The total number of new Gd-enhancing lesions from qualified MRI scans at Weeks 12, 16, 20, and 24, calculated as the sum of new Gd-enhancing lesions from these four scans. Gd-enhancing lesions are detected when Gd leaks into the perivascular space due to local breakdown of the blood-brain barrier, indicating the presence of active inflammation in periventricular lesions. The Intent-to-Treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study treatment (BG00012 or placebo).	
End point type	Primary
End point timeframe: Week 12 to Week 24	



<b>End point values</b>	ITT Population: Placebo	ITT Population: BG00012 240 mg BID		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	113	111		
Units: lesions				
arithmetic mean (standard deviation)	4.3 (± 8.2)	1.1 (± 5.46)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description: Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline number of Gd lesions.	
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	lesion mean ratio
Point estimate	0.164
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.101
upper limit	0.266

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description: Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline number of Gd lesions.	
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	negative binomial regression
Parameter estimate	percentage reduction (vs. placebo)
Point estimate	83.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	73.4
upper limit	89.9

<b>Statistical analysis title</b>	Sensitivity Analysis 1
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Wilcoxon rank sum test

<b>Statistical analysis title</b>	Sensitivity Analysis 2
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 <sup>[1]</sup>
Method	see footnote

Notes:

[1] - Based on exclusion of 1 subject with outlier values and subjects who tested positive for anti-aquaporin 4 (AQP4) antibody.

<b>Statistical analysis title</b>	Sensitivity Analysis 3
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 <sup>[2]</sup>
Method	see footnote

Notes:

[2] - Based on imputation with interpolation for missing values at a visit that has valid readings at the visits immediately prior and after the visit with the missing value.

## **Primary: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs): Part II**

End point title	Number of Subjects with Treatment-Emergent Adverse Events (TEAEs): Part II <sup>[3]</sup>
-----------------	---

End point description:

A treatment-emergent AE was defined as an AE that started or worsened on or after the date of the first dose of study treatment. The Safety population: analyses of the total BG00012 240 mg BID experience combined all data (Parts I and II) from subjects who received BG00012 in both Parts I and II with Part II only data from subjects who received BG00012 in Part II of the study after switching from placebo (in Part I).

End point type	Primary
End point timeframe:	
Up to 4.5 Years	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses are reported for this endpoint.

End point values	Part II: Placebo/BG00012 240 mg BID (Switchers):	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	105		
Units: subjects				
number (not applicable)	99	98		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects with Treatment-Emergent Serious Adverse Events (SAEs): Part II

End point title	Number of Subjects with Treatment-Emergent Serious Adverse Events (SAEs): Part II <sup>[4]</sup>
-----------------	--

End point description:

A SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the subject at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in a congenital anomaly/birth defect. The Safety population: analyses of the total BG00012 240 mg BID experience combined all data (Parts I and II) from subjects who received BG00012 in both Parts I and II with Part II only data from subjects who received BG00012 in Part II of the study after switching from placebo (in Part I).

End point type	Primary
----------------	---------

End point timeframe:

Up to 4.5 Years

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses are reported for this endpoint.

End point values	Part II: Placebo/BG00012 240 mg BID (Switchers):	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	105		
Units: subjects				
number (not applicable)	28	28		

## Statistical analyses

**Primary: Number of Subjects with Clinically Significant Laboratory Values Reported as Adverse Events: Part II**

End point title	Number of Subjects with Clinically Significant Laboratory Values Reported as Adverse Events: Part II <sup>[5]</sup>
End point description:	
Clinical laboratory evaluations included haematology, blood chemistry, lipid profile, and urinalysis. The Safety population: analyses of the total BG00012 240 mg BID experience combined all data (Parts I and II) from subjects who received BG00012 in both Parts I and II with Part II only data from subjects who received BG00012 in Part II of the study after switching from placebo (in Part I).	
End point type	Primary
End point timeframe:	
Up to 4.5 Years	

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses are reported for this endpoint.

End point values	Part II: Placebo/BG00012 240 mg BID (Switchers):	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	105		
Units: subjects				
number (not applicable)				
LYMPHOCYTE COUNT DECREASED	6	9		
ALANINE AMINOTRANSFERASE INCREASED	5	8		
ASPARTATE AMINOTRANSFERASE INCREASED	4	5		
BLOOD GLUCOSE INCREASED	0	3		
GAMMA-GLUTAMYLTRANSFERASE INCREASED	2	3		
WHITE BLOOD CELL COUNT DECREASED	4	3		
BLOOD URIC ACID INCREASED	0	2		
BLOOD BILIRUBIN INCREASED	0	1		
BLOOD CHOLESTEROL INCREASED	0	1		
BLOOD TRIGLYCERIDES INCREASED	0	1		
HAEMATOCRIT DECREASED	0	1		
HAEMOGLOBIN DECREASED	0	1		
LIVER FUNCTION TEST ABNORMAL	1	1		
NEUTROPHIL COUNT DECREASED	1	1		
PROTEIN URINE	1	1		
WHITE BLOOD CELLS URINE POSITIVE	0	1		
BETA 2 MICROGLOBULIN INCREASED	1	0		
BLOOD ALKALINE PHOSPHATASE INCREASED	1	0		
BLOOD URINE PRESENT	1	0		
EOSINOPHIL COUNT INCREASED	1	0		
HEPATIC ENZYME INCREASED	1	0		

LOW DENSITY LIPOPROTEIN INCREASED	1	0		
MEAN CELL VOLUME INCREASED	1	0		
OCCULT BLOOD	1	0		
OCCULT BLOOD POSITIVE	1	0		
TRANSAMINASES INCREASED	1	0		
URINARY CASTS	1	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects with Clinically Significant Changes in Vital Signs: Part II

End point title	Number of Subjects with Clinically Significant Changes in Vital Signs: Part II <sup>[6]</sup>
-----------------	---

End point description:

Vital signs were examined to determine the incidence of clinically relevant abnormalities and include diastolic and systolic blood pressure, heart rate, and temperature. The Safety population: analyses of the total BG00012 240 mg BID experience combined all data (Parts I and II) from subjects who received BG00012 in both Parts I and II with Part II only data from subjects who received BG00012 in Part II of the study after switching from placebo (in Part I).

End point type	Primary
----------------	---------

End point timeframe:

Up to 4.5 Years

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses are reported for this endpoint.

End point values	Part II: Placebo/BG00012 240 mg BID (Switchers):	Part II: BG00012 240 mg mg BID/BG00012 240 mg BID (Continuers)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	108	105		
Units: subjects				
number (not applicable)	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: MRI: Total Number of New Gd-Enhancing Lesions From Scans at Weeks 4 to 24: Part I

End point title	MRI: Total Number of New Gd-Enhancing Lesions From Scans at Weeks 4 to 24: Part I
-----------------	---

End point description:

The cumulative number of new Gd-enhancing lesions over the six MRI scans in the placebo-controlled

phase was calculated as the sum of the new Gd-enhancing lesions from the Week 4 to Week 24 scans. The ITT population was defined as all randomized subjects who received at least 1 dose of study treatment (BG00012 or placebo).

End point type	Secondary
End point timeframe:	
Week 4 to Week 24	

End point values	ITT Population: Placebo	ITT Population: BG00012 240 mg BID		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	113	111		
Units: lesions				
arithmetic mean (standard deviation)	6.5 ( $\pm$ 10.7)	2.6 ( $\pm$ 12.57)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline number of Gd lesions.

Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	lesion mean ratio
Point estimate	0.247
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.167
upper limit	0.366

Statistical analysis title	Statistical Analysis 2
----------------------------	------------------------

Statistical analysis description:

Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline number of Gd lesions.

Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
-------------------	--

Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	negative binomial regression
Parameter estimate	percentage reduction (vs. placebo)
Point estimate	75.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	63.4
upper limit	83.3

## Secondary: MRI: Total Number of New or Newly Enlarging T2 Lesions at Week 24 Compared to Baseline: Part I

End point title	MRI: Total Number of New or Newly Enlarging T2 Lesions at Week 24 Compared to Baseline: Part I
End point description:	The total number of new or newly-enlarging T2 hyperintense lesions at Week 24 compared to baseline. Lesions detected on T2-weighted sequences have been shown to represent a range of histopathology related to MS, including edema, inflammation, demyelination, gliosis, and axon loss. The ITT population was defined as all randomized subjects who received at least 1 dose of study treatment (BG00012 or placebo).
End point type	Secondary
End point timeframe:	Baseline, Week 24

End point values	ITT Population: Placebo	ITT Population: BG00012 240 mg BID		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	113	111		
Units: lesions				
arithmetic mean (standard deviation)	4.9 (± 6.23)	1.9 (± 3.42)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline volume of T2 lesions.
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID

Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	lesion mean ratio
Point estimate	0.368
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.258
upper limit	0.525

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description: Percentage change, 95% CI and p-value for comparison between the active and placebo groups, based on negative binomial regression, adjusted for region (Japan/Non-Japan) and baseline volume of T2 lesions.	
Comparison groups	ITT Population: Placebo v ITT Population: BG00012 240 mg BID
Number of subjects included in analysis	224
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	negative binomial regression
Parameter estimate	percentage reduction (vs. placebo)
Point estimate	63.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	47.5
upper limit	74.2



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

First dose of study treatment to the End of Study (Up to 4.5 Years)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

### Reporting groups

Reporting group title	Part I Placebo
-----------------------	----------------

Reporting group description:

Subjects randomized to placebo BID began dosing at 1 placebo capsule orally BID for the first 7 days and escalated to 2 placebo capsules orally BID from Day 8 through Week 24 (end of Part I).

Reporting group title	Part I BG00012 240 mg BID
-----------------------	---------------------------

Reporting group description:

Subjects randomized to BG00012 began dosing at 120 mg BG00012 (1 capsule orally BID) for the first 7 days and escalated to 240 mg BG00012 (2 capsules orally BID) from Day 8 through Week 24 (end of Part I).

Reporting group title	Part II: Placebo/BG00012 240 mg BID (Switchers)
-----------------------	---

Reporting group description:

"PBO/BG12" – Subjects who received placebo in Part I before receiving BG00012 240 milligram (mg) BID in Part II for up to 4.5 years.

Reporting group title	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)
-----------------------	---

Reporting group description:

"BG12/BG12" – Subjects who received BG00012 240 mg BID in Part I, continued receiving BG00012 in Part II for up to 4.5 years.

<b>Serious adverse events</b>	Part I Placebo	Part I BG00012 240 mg BID	Part II: Placebo/BG00012 240 mg BID (Switchers)
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 113 (14.16%)	13 / 111 (11.71%)	28 / 108 (25.93%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fallopian tube cancer			
subjects affected / exposed	1 / 113 (0.88%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Pregnancy			

subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 113 (0.00%)	1 / 111 (0.90%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somatoform disorder			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Protein urine			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			

subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug toxicity			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 113 (0.00%)	1 / 111 (0.90%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 113 (0.00%)	1 / 111 (0.90%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	0 / 113 (0.00%)	1 / 111 (0.90%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis relapse			
subjects affected / exposed	16 / 113 (14.16%)	10 / 111 (9.01%)	18 / 108 (16.67%)
occurrences causally related to treatment / all	2 / 22	1 / 15	0 / 29
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic neuritis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Hypertonic bladder			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Microalbuminuria			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			

subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Appendicitis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic tonsillitis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic inflammatory disease			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 113 (0.00%)	1 / 111 (0.90%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	1 / 108 (0.93%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 113 (0.00%)	0 / 111 (0.00%)	0 / 108 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)		
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 105 (26.67%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fallopian tube cancer			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somatoform disorder			

subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Protein urine			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clavicle fracture			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Drug toxicity			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		



Humerus fracture			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wrist fracture			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			

Epilepsy			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Multiple sclerosis relapse			
subjects affected / exposed	16 / 105 (15.24%)		
occurrences causally related to treatment / all	1 / 31		
deaths causally related to treatment / all	0 / 0		
Optic neuritis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorder			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Hypertonic bladder			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Microalbuminuria			

subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthritis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc disorder			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic tonsillitis			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystitis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic inflammatory disease			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pyelonephritis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Part I Placebo	Part I BG00012 240 mg BID	Part II: Placebo/BG00012 240 mg BID (Switchers)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	71 / 113 (62.83%)	85 / 111 (76.58%)	95 / 108 (87.96%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 113 (0.88%)	7 / 111 (6.31%)	5 / 108 (4.63%)
occurrences (all)	1	8	8
Lymphocyte count decreased			
subjects affected / exposed	0 / 113 (0.00%)	2 / 111 (1.80%)	6 / 108 (5.56%)
occurrences (all)	0	3	7
Vascular disorders			
Flushing			
subjects affected / exposed	10 / 113 (8.85%)	26 / 111 (23.42%)	38 / 108 (35.19%)
occurrences (all)	12	28	85
Hot flush			
subjects affected / exposed	1 / 113 (0.88%)	7 / 111 (6.31%)	4 / 108 (3.70%)
occurrences (all)	1	7	4
Nervous system disorders			

Dizziness subjects affected / exposed occurrences (all)	1 / 113 (0.88%) 1	3 / 111 (2.70%) 3	3 / 108 (2.78%) 5
Headache subjects affected / exposed occurrences (all)	2 / 113 (1.77%) 4	4 / 111 (3.60%) 5	12 / 108 (11.11%) 13
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	3 / 111 (2.70%) 3	4 / 108 (3.70%) 6
Multiple sclerosis relapse subjects affected / exposed occurrences (all)	31 / 113 (27.43%) 41	23 / 111 (20.72%) 31	39 / 108 (36.11%) 77
Paraesthesia subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	2 / 111 (1.80%) 2	8 / 108 (7.41%) 10
Blood and lymphatic system disorders Lymphopenia subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	2 / 111 (1.80%) 2	7 / 108 (6.48%) 10
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	2 / 113 (1.77%) 2	1 / 111 (0.90%) 1	5 / 108 (4.63%) 5
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	8 / 111 (7.21%) 11	8 / 108 (7.41%) 8
Abdominal pain upper subjects affected / exposed occurrences (all)	6 / 113 (5.31%) 8	5 / 111 (4.50%) 5	16 / 108 (14.81%) 22
Diarrhoea subjects affected / exposed occurrences (all)	6 / 113 (5.31%) 6	11 / 111 (9.91%) 12	15 / 108 (13.89%) 20
Dyspepsia subjects affected / exposed occurrences (all)	3 / 113 (2.65%) 3	2 / 111 (1.80%) 2	7 / 108 (6.48%) 8

Nausea subjects affected / exposed occurrences (all)	6 / 113 (5.31%) 7	10 / 111 (9.01%) 10	13 / 108 (12.04%) 19
Vomiting subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	5 / 111 (4.50%) 6	9 / 108 (8.33%) 13
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 113 (1.77%) 2	0 / 111 (0.00%) 0	6 / 108 (5.56%) 6
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)	2 / 113 (1.77%) 7  0 / 113 (0.00%) 0	8 / 111 (7.21%) 9  3 / 111 (2.70%) 4	10 / 108 (9.26%) 12  3 / 108 (2.78%) 4
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	4 / 113 (3.54%) 4	3 / 111 (2.70%) 4	6 / 108 (5.56%) 6
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Back pain subjects affected / exposed occurrences (all)  Pain in extremity subjects affected / exposed occurrences (all)	4 / 113 (3.54%) 6  3 / 113 (2.65%) 3  1 / 113 (0.88%) 1	1 / 111 (0.90%) 1  3 / 111 (2.70%) 3  2 / 111 (1.80%) 2	9 / 108 (8.33%) 10  4 / 108 (3.70%) 5  6 / 108 (5.56%) 8
Infections and infestations Cystitis subjects affected / exposed occurrences (all)  Gastroenteritis	0 / 113 (0.00%) 0	1 / 111 (0.90%) 1	7 / 108 (6.48%) 9

subjects affected / exposed occurrences (all)	0 / 113 (0.00%) 0	4 / 111 (3.60%) 4	3 / 108 (2.78%) 5
Herpes zoster subjects affected / exposed occurrences (all)	1 / 113 (0.88%) 1	0 / 111 (0.00%) 0	6 / 108 (5.56%) 6
Influenza subjects affected / exposed occurrences (all)	1 / 113 (0.88%) 1	2 / 111 (1.80%) 2	6 / 108 (5.56%) 8
Nasopharyngitis subjects affected / exposed occurrences (all)	28 / 113 (24.78%) 45	25 / 111 (22.52%) 28	41 / 108 (37.96%) 123
Upper respiratory tract infection subjects affected / exposed occurrences (all)	11 / 113 (9.73%) 17	5 / 111 (4.50%) 7	21 / 108 (19.44%) 43

<b>Non-serious adverse events</b>	Part II: BG00012 240 mg BID/BG00012 240 mg BID (Continuers)		
Total subjects affected by non-serious adverse events subjects affected / exposed	91 / 105 (86.67%)		
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	8 / 105 (7.62%) 16		
Lymphocyte count decreased subjects affected / exposed occurrences (all)	9 / 105 (8.57%) 15		
Vascular disorders Flushing subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 6		
Hot flush subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 5		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	6 / 105 (5.71%) 6		

Headache			
subjects affected / exposed	12 / 105 (11.43%)		
occurrences (all)	26		
Hypoaesthesia			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	7		
Multiple sclerosis relapse			
subjects affected / exposed	39 / 105 (37.14%)		
occurrences (all)	79		
Paraesthesia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Blood and lymphatic system disorders			
Lymphopenia			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	9		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	6		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 105 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	7		
Dyspepsia			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	4		
Nausea			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	7		



Vomiting subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 4		
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	6 / 105 (5.71%) 7		
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)	6 / 105 (5.71%) 7  10 / 105 (9.52%) 14		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	6 / 105 (5.71%) 7		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Back pain subjects affected / exposed occurrences (all)  Pain in extremity subjects affected / exposed occurrences (all)	15 / 105 (14.29%) 20  8 / 105 (7.62%) 10  4 / 105 (3.81%) 4		
Infections and infestations Cystitis subjects affected / exposed occurrences (all)  Gastroenteritis subjects affected / exposed occurrences (all)  Herpes zoster	8 / 105 (7.62%) 9  9 / 105 (8.57%) 9		

subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	7		
Influenza			
subjects affected / exposed	18 / 105 (17.14%)		
occurrences (all)	20		
Nasopharyngitis			
subjects affected / exposed	47 / 105 (44.76%)		
occurrences (all)	131		
Upper respiratory tract infection			
subjects affected / exposed	8 / 105 (7.62%)		
occurrences (all)	17		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 November 2012	The primary reason for this amendment was to extend the contraception requirement from 30 days after the last dose of study treatment through the Final Safety Follow-Up Visit 12 weeks after the last dose of study treatment.
22 November 2013	The primary reasons for this amendment were to: - Open the study in the Czech Republic and Poland in addition to Japan, South Korea, and Taiwan. Although China was originally included, the study was withdrawn from China prior to study approval in that country. The title of the study was updated to reflect these changes. - Recommend that visits for female subjects be scheduled when the subject was not menstruating as a precaution against contamination of urine samples. - Anti-APQ4 antibody testing was to occur at the first Relapse Assessment Visit but was not required at any subsequent Relapse Assessment Visit. - Weight was added as an assessment at the End of Study/Premature Withdrawal/Final Safety Follow-Up Visit. - Clarify that MRI was not to be performed within 28 days after completing a course of steroids. - Clarify that if a subject had positive urinalysis test at Screening and the etiology was known (e.g., due to menses or urinary tract infection in the case of hematuria, or due to recent steroid use or elevated serum glucose in the case of glycosuria), a repeat test was not required.
10 December 2014	The primary reasons for this amendment were to: - Enable the early identification of subjects in Parts I or II who are at risk for developing severe, prolonged lymphopenia, and to provide additional guidance on the management of such subjects. In addition, lymphocyte and subset counts have been supplemented as an exploratory endpoint with the objective to study the impact of BG00012 treatment on lymphocytes and the recovery of lymphocyte count in patients with lymphopenia. - Extend the duration of study participation from 28 or 40 weeks to 28 to 52 weeks to reflect the additional safety follow-up for subjects with abnormally low lymphocyte counts. Subjects who completed Part I and did not enroll in Part II of the study or subjects who permanently discontinued study treatment for any reason and had a lymphocyte count <LLN were to be followed until the lymphocyte count was ≥LLN or until 24 weeks after the last dose (whichever was sooner). - Clarify that the use of alternative MS therapies was allowed only after the Investigators had contacted Biogen or its designee to determine their necessity in subjects who completed Part I and did not enroll in Part II of the study or subjects who permanently discontinued study treatment. - Country was added as a covariate for the statistical modelling of additional endpoints to be consistent with the analysis of the primary and secondary endpoints. - If lymphocyte count remains <500/mm <sup>3</sup> for ≥24 weeks consecutively, study treatment will be permanently discontinued, and recovery of lymphocytes will be followed.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported